TABLE 4.
Univariate analysis | |||
---|---|---|---|
OR | 95% CI | P value | |
Region | <.001 | ||
HVH | 1.00 | Refa | |
LVH | 2.88 | 1.76–4.72 | |
Age (years) | .01 | ||
<50 | 0.19 | 0.04–0.79 | |
50–59 | 0.51 | 0.25–1.04 | |
60–69 | 1.00 | Refa | |
>70 | 1.20 | 0.70–2.04 | |
Gender | .20 | ||
Male | 1.00 | Refa | |
Female | 0.67 | 0.36–1.24 | |
Comorbidity | <.001 | ||
No | 1.00 | Refa | |
1 organ system | 2.02 | 1.06–3.86 | |
2 organ systems | 4.51 | 2.30–8.85 | |
≥3 organ systems | 4.97 | 1.92–12.83 | |
Histology | .97 | ||
Adenocarcinoma | 1.00 | Refa | |
Squamous | 0.99 | 0.60–1.65 | |
Stage | .24 | ||
I | 1.00 | Refa | |
II | 0.50 | 0.24–1.04 | |
III | 0.80 | 0.39–1.63 | |
IV | 0.65 | 0.26–1.61 | |
Tumor localization | .33 | ||
Cervical/mid esophagus | 1.00 | Refa | |
Distal esophagus/gastroesophageal junction | 1.41 | 0.71–2.80 | |
Neoadjuvant treatment | .14 | ||
No | 1.00 | Refa | |
Yes | 0.49 | 0.20–1.25 | |
Surgical approach | .31 | ||
Transhiatal | 1.00 | Refa | |
Transthoracic | 1.51 | 0.90–2.54 | .12 |
Anastomosis | .46 | ||
Cervical | 1.00 | Refa | |
Thoracic | 1.52 | 0.77–3.01 | |
Abdominal | 1.26 | 0.52–3.04 |
a Ref, reference category.